Arv dose protocol
antiretroviral ARV dosing protocol adults
Use of Antiretroviral Agents in Pediatric HIV Infection
Page 458
ARV dose HIV treatment regimen first line second line
Use of Antiretroviral Agents in Pediatric HIV Infection
Page 434
| Regimen | Dose | Notes |
|---|---|---|
| Bictegravir/TAF/FTC (Biktarvy) | 1 tablet once daily | With or without food |
| Dolutegravir + TAF/FTC (DTG + Descovy) | DTG 50 mg once daily + 1 Descovy tablet once daily | With or without food |
| Dolutegravir/Lamivudine (Dovato) | 1 tablet once daily | Not for baseline HIV RNA >500,000 or HBV co-infection |
| Cabotegravir + Rilpivirine (Cabenuva) | Monthly or every 2 months IM injection | For virologically suppressed patients only |
| Regimen | Dose | Notes |
|---|---|---|
| Doravirine (DOR)/3TC/TDF (Delstrigo) | 1 tablet once daily | ART-naive or virologically suppressed (HIV RNA <50) on stable regimen, no prior treatment failure |
| Rilpivirine/FTC/TDF (Complera) | 1 tablet once daily with ≥500 kcal meal | ART-naive with baseline HIV RNA ≤100,000 copies/mL; or suppressed on 1st/2nd regimen |
| Efavirenz 600 mg/3TC/TDF (Symfi) | 1 tablet once daily | Take on empty stomach |
| Efavirenz 400 mg/3TC/TDF (Symfi Lo) | 1 tablet once daily | Take on empty stomach |
| Regimen | Dose | Notes |
|---|---|---|
| Elvitegravir/Cobicistat/FTC/TDF (Stribild) | 1 tablet once daily | Administer with food; for ART-naive or virologically suppressed (HIV RNA <50) with no prior failure |
| Doravirine (DOR) alone | 100 mg once daily | For ART-naive or virologically suppressed, no prior resistance to DOR |
| Situation | Modification |
|---|---|
| Pregnancy | DTG preferred; avoid EFV in 1st trimester |
| TB co-infection | Use EFV 600 mg-based regimen (avoid PIs); rifabutin if PI-based required |
| Renal impairment | TAF preferred over TDF; dose-adjust if needed |
| Hepatic impairment | Avoid PIs with severe hepatic disease |
| HBV co-infection | Include TDF or TAF (dual HBV/HIV active) |
Note: This is a clinical reference summary. Always consult current DHHS or WHO guidelines and individualize therapy based on patient-specific factors including resistance profile, comorbidities, drug interactions, and adherence considerations.
A 45 year old lady presents with complaint of epigastric pain for 1 day and nausea and vomiting. Vomit after anything she eats or drinks. Vomit is white is color, no foul smelling. Give me diagnosis and treatment
| # | Diagnosis | Key Supporting Features |
|---|---|---|
| 1 | Acute Gastritis | Epigastric pain, nausea/vomiting, white vomit (no bile/blood), common in women |
| 2 | Peptic Ulcer Disease (PUD) | Epigastric pain, postprandial vomiting, 45-year-old age group |
| 3 | Functional Dyspepsia | Epigastric pain, bloating, nausea; diagnosis of exclusion |
| 4 | Acute Pancreatitis | Epigastric pain radiating to back, nausea/vomiting — consider especially if pain is severe |
| 5 | Gastric Outlet Obstruction | Persistent vomiting of undigested food, non-bilious white vomit — a serious complication to rule out |
| 6 | GERD / Gastroparesis | Postprandial symptoms, nausea, white vomit |
White, non-foul-smelling vomit (undigested food/gastric secretions, no bile staining, no feculent odor) is particularly consistent with gastric origin — pointing to gastritis, PUD, or early gastric outlet obstruction.
| Drug | Dose |
|---|---|
| PPI (e.g., Omeprazole) | 20 mg BD |
| Amoxicillin | 1 g BD |
| Clarithromycin | 500 mg BD |
Evidence strongly supports that H. pylori eradication virtually eliminates ulcer recurrence — Textbook of Family Medicine, p. 1125